LifeHub’s first project aims to develop AI-enabled radiology

Sensyne Health has extended its collaboration with Bayer to work on novel projects at the LifeHub UK centre in Reading.

Launched on October 10, LifeHub UK forms part of a global network of Bayer innovation hubs. It is designed to accelerate and optimise disease detection and data-driven drug discovery by enabling AI-enabled imaging solutions.

The first project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation. The project will analyse research from three million anonymised, ethically-sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of diagnosis and increase efficiency for patients.

Bayer board member for innovation Kemal Malik said: “We firmly believe that AI has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments. LifeHub UK’s roadmap is a perfect fit with Bayer’s Open Innovation strategy.”

Picture: Bayer board member for innovation Kemal Malik, secretary of state for health and social care Rt Hon Matt Hancock, head of LifeHub UK Dr Diana Madeiros Placido, managing director of Bayer Plc Lars Bruening and Sensyne Health chief executive The RT Hon the Lord Drayson.

Published on page 1 of the November 2019 issue of RAD Magazine.